AstraZeneca reportedly considering $400 billion merger with Bristol Myers Squibb
Quick Look
U.K. pharmaceutical giant AstraZeneca is reportedly discussing a potential $400 billion merger with U.S. competitor Bristol Myers Squibb, a deal that would be one of the largest in history, according to the Financial Times.
AI-generated summary
Why It Matters
U.K. pharmaceutical giant AstraZeneca is reportedly considering a merger with U.S. competitor Bristol Myers Squibb, potentially valuing the combined company at $400 billion.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb , in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
It's still unclear whether the deal will come together, but the companies have been discussing a merger over the last few months, sources told the FT.
The merger would be one of the largest in history.
AstraZeneca and Bristol Myers Squibb did not immediately respond to a CNBC request for comment.
What to Watch
AI outlook — possibilities, not facts
AstraZeneca and Bristol Myers Squibb will continue merger discussions.
Likely · Within weeks
Open Questions
- Will the merger deal come together?
- What are the specific terms of the discussions?
